Logo

Novo Nordisk's Rybelsus (semaglutide) Receives FDA's Approval as the First Oral GLP-1 analog for Type 2 Diabetes

Share this

Novo Nordisk's Rybelsus (semaglutide) Receives FDA's Approval as the First Oral GLP-1 analog for Type 2 Diabetes

Shots:

  • The FDA’s approval is based on 10 PIONEER clinical studies assessing Rybelsus vs sitagliptin- empagliflozin and liraglutide in 9-543 patients with T2D as an adjunct to diet & exercise
  • The clinical studies resulted in A1C reduction as 1EPs & reduction in body weights as 2EPs. Additionally- in H1’19- Novo Nordisk acquired a tableting and packaging facility in Durham to meet anticipated supply needs for Rybelsus
  • Rybelsus (qd) is an oral glucagon-like peptide-1 (GLP-1) analog- approved in two therapeutic doses 7/14mg with its expected availability in the US in Q4’19 and is under EMA & PMDA’s review. The US FDA is also reviewing Ryblesus for an additional indication- reducing the risk of MACE with an expected decision in Q1’20

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Novo Nordisk


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions